Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Plasmid-only rescue of influenza A virus vaccine candidates.

Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, García-Sastre A, Palese P.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1965-73. Review.

2.

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.

de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA.

J Virol. 2005 Oct;79(19):12401-7.

3.

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM.

Vaccine. 2006 Mar 15;24(12):2176-85. Epub 2005 Nov 10.

PMID:
16310896
4.

Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.

Jadhao SJ, Lee CW, Sylte M, Suarez DL.

Vaccine. 2009 Oct 19;27(44):6247-60. doi: 10.1016/j.vaccine.2009.07.110. Epub 2009 Aug 15.

PMID:
19686695
5.

Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs.

Solórzano A, Webby RJ, Lager KM, Janke BH, García-Sastre A, Richt JA.

J Virol. 2005 Jun;79(12):7535-43.

6.

A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin.

Stech J, Garn H, Wegmann M, Wagner R, Klenk HD.

Nat Med. 2005 Jun;11(6):683-9. Epub 2005 May 29.

PMID:
15924146
7.

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza.

Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, Mundt E, Schirrmeier H, Mebatsion T, Mettenleiter TC, Römer-Oberdörfer A.

Proc Natl Acad Sci U S A. 2006 May 23;103(21):8197-202. Epub 2006 May 22.

8.

Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.

Stech J.

Expert Rev Vaccines. 2008 Aug;7(6):739-43. doi: 10.1586/14760584.7.6.739. Review.

PMID:
18665773
9.

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y.

Virology. 2003 Jan 5;305(1):192-200.

10.

The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.

Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J.

Vaccine. 2008 Feb 13;26(7):956-65. doi: 10.1016/j.vaccine.2007.11.052. Epub 2007 Dec 10.

PMID:
18164519
13.

From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

Wood JM, Robertson JS.

Nat Rev Microbiol. 2004 Oct;2(10):842-7. Review.

PMID:
15378048
14.

Rescue of influenza A virus from recombinant DNA.

Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A.

J Virol. 1999 Nov;73(11):9679-82.

15.

A plasmid-based reverse genetics system for influenza A virus.

Pleschka S, Jaskunas R, Engelhardt OG, Zürcher T, Palese P, García-Sastre A.

J Virol. 1996 Jun;70(6):4188-92.

16.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
17.

The virulence of the 1918 pandemic influenza virus: unraveling the enigma.

Taubenberger JK.

Arch Virol Suppl. 2005;(19):101-15.

PMID:
16355870
18.

Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.

Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, Li Y, Wang X, Ge J, Bu Z, Chen H.

Antiviral Res. 2007 Sep;75(3):234-41. Epub 2007 Apr 9.

PMID:
17451817
19.

The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.

Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M, Kawaoka Y.

Vaccine. 2006 Apr 24;24(17):3669-76. Epub 2005 Jul 21.

PMID:
16378663
20.

Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A.

J Virol. 2005 Aug;79(16):10672-7.

Supplemental Content

Support Center